JP2012523438A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012523438A5 JP2012523438A5 JP2012504929A JP2012504929A JP2012523438A5 JP 2012523438 A5 JP2012523438 A5 JP 2012523438A5 JP 2012504929 A JP2012504929 A JP 2012504929A JP 2012504929 A JP2012504929 A JP 2012504929A JP 2012523438 A5 JP2012523438 A5 JP 2012523438A5
- Authority
- JP
- Japan
- Prior art keywords
- par
- p1i3pal
- agent
- signaling activity
- medium
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102000032744 PAR-1 Receptor Human genes 0.000 claims 34
- 108010070519 PAR-1 Receptor Proteins 0.000 claims 34
- 239000003795 chemical substances by application Substances 0.000 claims 18
- 230000011664 signaling Effects 0.000 claims 18
- 230000000694 effects Effects 0.000 claims 14
- 101700049451 lppL Proteins 0.000 claims 12
- 210000001772 Blood Platelets Anatomy 0.000 claims 9
- 229920001184 polypeptide Polymers 0.000 claims 9
- 238000003776 cleavage reaction Methods 0.000 claims 7
- 102000000380 Matrix Metalloproteinase 1 Human genes 0.000 claims 6
- 108010016113 Matrix Metalloproteinase 1 Proteins 0.000 claims 6
- 102000024609 PAR family Human genes 0.000 claims 6
- 108091011803 PAR family Proteins 0.000 claims 6
- 229960005261 Aspartic Acid Drugs 0.000 claims 5
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims 5
- 235000003704 aspartic acid Nutrition 0.000 claims 5
- 125000001116 prolino group Chemical group [H]OC(=O)C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 claims 5
- 230000003042 antagnostic Effects 0.000 claims 4
- 239000005557 antagonist Substances 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- 239000011159 matrix material Substances 0.000 claims 4
- 230000037361 pathway Effects 0.000 claims 4
- 235000018102 proteins Nutrition 0.000 claims 4
- 102000004169 proteins and genes Human genes 0.000 claims 4
- 108090000623 proteins and genes Proteins 0.000 claims 4
- 230000036499 Half live Effects 0.000 claims 3
- 229940079593 drugs Drugs 0.000 claims 3
- 101700067074 MAPK Proteins 0.000 claims 2
- 101710041325 MAPKAPK2 Proteins 0.000 claims 2
- ZBGXUVOIWDMMJE-QHNZEKIYSA-N Vorapaxar Chemical compound C(/[C@@H]1[C@H]2[C@H](C(O[C@@H]2C)=O)C[C@H]2[C@H]1CC[C@H](C2)NC(=O)OCC)=C\C(N=C1)=CC=C1C1=CC=CC(F)=C1 ZBGXUVOIWDMMJE-QHNZEKIYSA-N 0.000 claims 2
- 230000002797 proteolythic Effects 0.000 claims 2
- 101710024887 rl Proteins 0.000 claims 2
- 101700045897 spk-1 Proteins 0.000 claims 2
- 229960005044 vorapaxar Drugs 0.000 claims 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N D-Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 claims 1
- 230000004913 activation Effects 0.000 claims 1
- 125000000539 amino acid group Chemical group 0.000 claims 1
- 239000007864 aqueous solution Substances 0.000 claims 1
- 230000024881 catalytic activity Effects 0.000 claims 1
- 239000008103 glucose Substances 0.000 claims 1
Claims (29)
- 血小板の保存又は輸送のための媒体であって、前記媒体中に含まれる血小板上のプロテアーゼ活性化受容体−1(PAR−1)の39位のアスパラギン酸(D39)と40位のプロリン(P40)の間でのタンパク質切断を実質的に阻害する有効濃度の薬剤を含む、媒体。
- PARファミリーメンバーのpepducinリポペプチドを更に含む、請求項1に記載の媒体。
- 前記PARファミリーメンバーのpepducinリポペプチドが、PAR−1pepducinリポペプチドを含む、請求項2に記載の媒体。
- 前記PAR−1pepducinリポペプチドが、P1i3pal−7、P1i3pal−12、P1i3pal−12S、P1i3pal−10S、P1i1pal−11、P1i2pal−7、P1i2pal−11、P1i2pal−16、P1i2pal−21、P1i4pal13、及びP1i4pal13Rからなる群から選択される、請求項3に記載の媒体。
- グルコースを更に含む水溶液である、請求項1に記載の媒体。
- その中に含まれる正常血小板の平均半減期が約5日以上である、請求項1に記載の媒体。
- その中に含まれる正常血小板の平均半減期が約1ヶ月以上である、請求項1に記載の媒体。
- その中に含まれる正常血小板の平均半減期が約6ヶ月以上である、請求項1に記載の媒体。
- 血小板の保存又は輸送のための媒体であって、マトリックスメタロプロテアーゼ−1(MMP−1)の活性化又はMMP−1酵素活性を阻害する有効濃度の薬剤を含む、媒体。
- 血小板の保存又は輸送のための媒体であって、39位のアスパラギン酸(D39)と40位のプロリン(P40)の間でのプロテアーゼ活性化受容体−1(PAR−1)のタンパク質切断により生じるPAR−1シグナル伝達活性を実質的に阻害する有効濃度の薬剤を含む、媒体。
- 前記薬剤が、PARファミリーメンバーのpepducinリポペプチドを含む、請求項10に記載の媒体。
- 前記PARファミリーメンバーのpepducinリポペプチドが、PAR−1pepducinリポペプチドを含む、請求項11に記載の媒体。
- 前記PAR−1pepducinリポペプチドが、P1i3pal−7、P1i3pal−12、P1i3pal−12S、P1i3pal−10S、P1i1pal−11、P1i2pal−7、P1i2pal−11、P1i2pal−16、P1i2pal−21、P1i4pal13、及びP1i4pal13Rからなる群から選択される、請求項12に記載の媒体。
- 前記薬剤がSCH 530348を含む、請求項10に記載の媒体。
- 単離されたポリペプチドであって、配列が、ヒトプロテアーゼ活性化受容体−1(PAR−1)の39位のアスパラギン酸(D39)と40位のプロリン(P40)の間でのタンパク質切断により生じる2つの断片の一方の連続する5個以上のアミノ酸残基を含み、前記ポリペプチドが更に、前記タンパク質切断により生じた切断部位で一方の末端が終わる、単離されたポリペプチド。
- 前記ポリペプチドが、N末端にプロリンを有する、請求項15に記載の単離されたポリペプチド。
- PRSFLLRN(配列番号1)のポリペプチド配列である、請求項15に記載の単離されたポリペプチド。
- PAR−1アンタゴニストを同定する方法であって、
(a)請求項72に記載の単離されたポリペプチドを用意する工程;
(b)候補薬剤を用意する工程;
(c)前記候補薬剤の存在下で血小板を前記単離されたポリペプチドに接触させる工程;
(d)PAR−1シグナル伝達活性を測定する工程;及び
(e)前記候補薬剤存在下での前記PAR−1シグナル伝達活性を前記候補薬剤非存在下での前記PAR−1シグナル伝達活性と比較する工程
を含み、前記候補薬剤非存在下でのPAR−1シグナル伝達活性と比べた前記候補薬剤存在下でのPAR−1シグナル伝達活性の少なくとも10%の低下により、前記候補薬剤がPAR−1アンタゴニストとして同定される、方法。 - 前記PAR−1シグナル伝達活性が、Rho−GTP経路のシグナル伝達又はMAPK経路のシグナル伝達を含む、請求項18に記載の方法。
- PAR−1アンタゴニストを同定する方法であって、
(a)活性化MMP−1を用意する工程;
(b)候補薬剤を用意する工程;
(c)MMP−1がPAR−1を切断する条件下で前記候補薬剤存在下にて血小板を前記活性化MMP−1に接触させる工程;
(d)PAR−1シグナル伝達活性を測定する工程;及び
(e)前記候補薬剤存在下での前記PAR−1シグナル伝達活性を前記候補薬剤非存在下での前記PAR−1シグナル伝達活性と比較する工程;
を含み、前記候補薬剤非存在下でのPAR−1シグナル伝達活性と比べた前記候補薬剤存在下でのPAR−1シグナル伝達活性の少なくとも10%の低下により、前記候補薬剤がPAR−1アンタゴニストとして同定される、方法。 - 前記PAR−1シグナル伝達活性が、Rho−GTP経路のシグナル伝達又はMAPK経路のシグナル伝達を含む、請求項20に記載の方法。
- 前記患者のプロテアーゼ活性化受容体−1(PAR−1)の39位のアスパラギン酸(D39)と40位のプロリン(P40)の間でのタンパク質切断を実質的に阻害する薬剤を含むマトリックス層でコーティングされた医療器具。
- 39位のアスパラギン酸(D39)と40位のプロリン(P40)の間でのプロテアーゼ活性化受容体−1(PAR−1)のタンパク質切断により生じるPAR−1シグナル伝達活性を実質的に阻害する薬剤を含むマトリックス層でコーティングされた医療器具。
- 前記薬剤がSCH 530348を含む、請求項23に記載の医療器具。
- 前記マトリックス層が、生体適合性ペプチドマトリックスである、請求項23に記載の医療器具。
- 前記器具が移植可能である、請求項23に記載の医療器具。
- 前記薬剤が、PARファミリーメンバーのpepducinリポペプチドを含む、請求項23に記載の医療器具。
- 前記PARファミリーメンバーのpepducinリポペプチドが、PAR−1pepducinリポペプチドを含む、請求項27に記載の医療器具。
- 前記PAR−1pepducinリポペプチドが、P1i3pal−7、P1i3pal−12、P1i3pal−12S、P1i3pal−10S、P1i1pal−11、P1i2pal−7、P1i2pal−11、P1i2pal−16、P1i2pal−21、P1i4pal13、及びP1i4pal13Rからなる群から選択される、請求項28に記載の医療器具。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16836009P | 2009-04-10 | 2009-04-10 | |
US16835309P | 2009-04-10 | 2009-04-10 | |
US61/168,353 | 2009-04-10 | ||
US61/168,360 | 2009-04-10 | ||
PCT/US2010/030783 WO2010118435A2 (en) | 2009-04-10 | 2010-04-12 | Par-1 activation by metalloproteinase-1 (mmp-1) |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2012523438A JP2012523438A (ja) | 2012-10-04 |
JP2012523438A5 true JP2012523438A5 (ja) | 2013-05-30 |
Family
ID=42936908
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2012504929A Pending JP2012523438A (ja) | 2009-04-10 | 2010-04-12 | メタロプロテイナーゼ−1(mmp−1)によるpar−1活性化 |
Country Status (7)
Country | Link |
---|---|
US (3) | US20120121706A1 (ja) |
EP (3) | EP3061460A1 (ja) |
JP (1) | JP2012523438A (ja) |
AU (1) | AU2010233089B2 (ja) |
CA (1) | CA2758322C (ja) |
DE (1) | DE202010018378U1 (ja) |
WO (1) | WO2010118435A2 (ja) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012090207A2 (en) * | 2010-12-30 | 2012-07-05 | Hadasit Medical Research Services & Development Limited | Par1 and par2 c-tail peptides and peptide mimetics |
EP2606828B1 (en) * | 2011-12-20 | 2018-04-11 | Angioclinic AG | Hyaluronic acid and its use for treating venous insufficiency and varicose veins |
JP2014514259A (ja) * | 2011-03-02 | 2014-06-19 | アクイラス ファーマシューティカルズ, インコーポレイテッド | 疼痛および他の障害の処置のための化合物および方法 |
WO2012139137A2 (en) * | 2011-04-08 | 2012-10-11 | Tufts Medical Center, Inc. | Pepducin design and use |
MY201293A (en) | 2012-01-12 | 2024-02-15 | Bioverativ Therapeutics Inc | Chimeric factor viii polypeptides and uses thereof |
RS63870B1 (sr) | 2012-02-15 | 2023-01-31 | Bioverativ Therapeutics Inc | Sastavi faktora viii i postupci za pravljenje i upotrebu istih |
JP6383666B2 (ja) | 2012-02-15 | 2018-08-29 | バイオベラティブ セラピューティクス インコーポレイテッド | 組換え第viii因子タンパク質 |
WO2013183725A1 (ja) * | 2012-06-06 | 2013-12-12 | 国立大学法人九州大学 | 非ヒトモデル動物、非ヒトモデル動物の作製方法及び抗血栓薬のスクリーニング方法 |
DK2882450T3 (da) | 2012-07-11 | 2020-02-24 | Bioverativ Therapeutics Inc | Faktor viii-kompleks med xten og von willebrand-faktorprotein samt anvendelser deraf |
WO2014160037A2 (en) * | 2013-03-14 | 2014-10-02 | The Regents Of The University Of California | Activatable membrane-interacting peptides and methods of use |
WO2014210547A1 (en) * | 2013-06-28 | 2014-12-31 | Biogen Idec Ma Inc. | Thrombin cleavable linker |
US10548953B2 (en) | 2013-08-14 | 2020-02-04 | Bioverativ Therapeutics Inc. | Factor VIII-XTEN fusions and uses thereof |
TW201602109A (zh) | 2013-09-25 | 2016-01-16 | 維泰克斯製藥公司 | 作為par-2訊息傳遞路徑之抑制劑之咪唑并嗒 |
AU2015204646B2 (en) | 2014-01-10 | 2020-08-27 | Bioverativ Therapeutics Inc. | Factor VIII chimeric proteins and uses thereof |
WO2015107139A1 (en) * | 2014-01-17 | 2015-07-23 | Proyecto De Biomedicina Cima, S.L. | Compounds for use as antifibrinolytic agents |
US20160000791A1 (en) | 2014-07-07 | 2016-01-07 | Mayo Foundation For Medical Education And Research | Par1 modulation to alter myelination |
WO2016205062A1 (en) * | 2015-06-15 | 2016-12-22 | Shifa Biomedical Corporation | Antithrombotic therapies |
CN106551944A (zh) * | 2015-09-25 | 2017-04-05 | 南开大学 | 四环素类衍生物作为par-1抑制剂的用途 |
WO2019131941A1 (ja) * | 2017-12-28 | 2019-07-04 | 株式会社カネカ | 細胞凝集抑制剤 |
WO2020172113A1 (en) * | 2019-02-18 | 2020-08-27 | Lankenau Institute For Medical Research | Scar reducing wound closure materials |
US11419809B2 (en) | 2019-06-27 | 2022-08-23 | L'oreal | Hair treatment compositions and methods for treating hair |
KR102612229B1 (ko) * | 2021-05-21 | 2023-12-08 | 가천대학교 산학협력단 | N-[(4'-브로모[1,1'-바이페닐]-4-일)설포닐]-l-발린 또는 이의 약제학적으로 허용 가능한 염을 포함하는 아밀로이드 베타의 올리고머화 및 피브릴화 억제용 조성물 |
Family Cites Families (69)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2990331A (en) | 1956-11-23 | 1961-06-27 | Pfizer & Co C | Stable solutions of salts of tetracyclines for parenteral administration |
US2980584A (en) | 1957-10-29 | 1961-04-18 | Pfizer & Co C | Parenteral magnesium oxytetracycline acetic or lactic acid carboxamide vehicle preparation |
US3062717A (en) | 1958-12-11 | 1962-11-06 | Pfizer & Co C | Intramuscular calcium tetracycline acetic or lactic acid carboxamide vehicle preparation |
US3165531A (en) | 1962-03-08 | 1965-01-12 | Pfizer & Co C | 13-substituted-6-deoxytetracyclines and process utilizing the same |
US3454697A (en) | 1965-06-08 | 1969-07-08 | American Cyanamid Co | Tetracycline antibiotic compositions for oral use |
NL6607516A (ja) | 1966-05-31 | 1967-12-01 | ||
DE1767891C3 (de) | 1968-06-28 | 1980-10-30 | Pfizer | Verfahren zur Herstellung von wäßrigen arzneilichen Lösungen für die parenterale, perorale und lokale Anwendung mit einem Gehalt an einem Tetracyclinderivat |
US3784701A (en) | 1970-09-21 | 1974-01-08 | American Cyanamid Co | Compositions containing substituted benzoylpropionic acids and method of use to treat inflammation and pain |
US3957980A (en) | 1972-10-26 | 1976-05-18 | Pfizer Inc. | Doxycycline parenteral compositions |
DE2442829A1 (de) | 1974-09-06 | 1976-03-18 | Merck Patent Gmbh | Tetracyclische verbindungen und verfahren zu ihrer herstellung |
US4018889A (en) | 1976-01-02 | 1977-04-19 | Pfizer Inc. | Oxytetracycline compositions |
US4126680A (en) | 1977-04-27 | 1978-11-21 | Pfizer Inc. | Tetracycline antibiotic compositions |
FR2530247B1 (fr) | 1982-07-13 | 1986-05-16 | Sanofi Sa | Nouveaux derives de la thieno (3, 2-c) pyridine, leur procede de preparation et leur application therapeutique |
GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
US4868103A (en) | 1986-02-19 | 1989-09-19 | Enzo Biochem, Inc. | Analyte detection by means of energy transfer |
GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
FR2623810B2 (fr) | 1987-02-17 | 1992-01-24 | Sanofi Sa | Sels de l'alpha-(tetrahydro-4,5,6,7 thieno(3,2-c) pyridyl-5) (chloro-2 phenyl) -acetate de methyle dextrogyre et compositions pharmaceutiques en contenant |
US5080891A (en) | 1987-08-03 | 1992-01-14 | Ddi Pharmaceuticals, Inc. | Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols |
US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
US5525348A (en) | 1989-11-02 | 1996-06-11 | Sts Biopolymers, Inc. | Coating compositions comprising pharmaceutical agents |
US5270163A (en) | 1990-06-11 | 1993-12-14 | University Research Corporation | Methods for identifying nucleic acid ligands |
DK0786469T3 (da) | 1990-06-11 | 2006-07-10 | Gilead Sciences Inc | Nukleinsyreligander |
KR927003521A (ko) | 1990-12-03 | 1992-12-18 | 죤 에드워드 베리만 | 펩티딜(peptidyl) 유도체 |
EP0519596B1 (en) | 1991-05-17 | 2005-02-23 | Merck & Co. Inc. | A method for reducing the immunogenicity of antibody variable domains |
FI101150B (fi) | 1991-09-09 | 1998-04-30 | Sankyo Co | Menetelmä lääkeaineina käyttökelpoisten tetrahydrotienopyridiinin johd annaisten valmistamiseksi |
DE69326967T2 (de) | 1992-01-17 | 2000-06-15 | Lakowicz Joseph R | Phasenmodulationsenergieübertragungsfluoroimmunassay |
GB9211707D0 (en) | 1992-06-03 | 1992-07-15 | Celltech Ltd | Peptidyl derivatives |
DE69333969T2 (de) | 1992-10-30 | 2006-09-14 | The General Hospital Corp., Boston | Wechselwirkendes Fallensystem zur Isolierung von Proteinen |
US5455258A (en) | 1993-01-06 | 1995-10-03 | Ciba-Geigy Corporation | Arylsulfonamido-substituted hydroxamic acids |
US5552419A (en) | 1993-01-06 | 1996-09-03 | Ciba-Geigy Corporation | Arylsulfonamido-substituted hydroxamic acids |
GB9323165D0 (en) | 1993-11-10 | 1994-01-05 | Chiros Ltd | Compounds |
DE69509401T2 (de) | 1994-10-05 | 1999-08-19 | Darwin Discovery Ltd | Peptidische verbindungen und deren therapeutische verwendung als metalloproteinase-inhibitoren |
US5789434A (en) | 1994-11-15 | 1998-08-04 | Bayer Corporation | Derivatives of substituted 4-biarylbutyric acid as matrix metalloprotease inhibitors |
US6326155B1 (en) | 1995-03-20 | 2001-12-04 | Dyax Corp. | Engineering affinity ligands for macromolecules |
US5837313A (en) | 1995-04-19 | 1998-11-17 | Schneider (Usa) Inc | Drug release stent coating process |
FR2779726B1 (fr) | 1998-06-15 | 2001-05-18 | Sanofi Sa | Forme polymorphe de l'hydrogenosulfate de clopidogrel |
US20050020607A1 (en) | 1999-05-03 | 2005-01-27 | Newton Roger Schofield | Statin-MMP inhibitor combinations |
US6858577B1 (en) | 1999-06-29 | 2005-02-22 | Ortho-Mcneil Pharmaceutical, Inc. | Indole peptidomimetics as thrombin receptor antagonists |
EP2348047A1 (en) * | 2000-04-21 | 2011-07-27 | New England Medical Center | G protein coupled receptor (GPCR) agonists and antagonists and methods of activating and inhibiting GPCR using the same |
US7696168B2 (en) | 2000-04-21 | 2010-04-13 | Tufts Medical Center, Inc. | G protein coupled receptor agonists and antagonists and methods of activating and inhibiting G protein coupled receptors using the same |
JP4469467B2 (ja) * | 2000-06-29 | 2010-05-26 | 帝人株式会社 | 細胞増殖抑制剤 |
PT1298132E (pt) | 2000-07-06 | 2007-01-31 | Sankyo Co | Sais de adição de ácido derivados de hidropiridina |
US7186693B2 (en) | 2001-08-16 | 2007-03-06 | Kimberly - Clark Worldwide, Inc. | Metalloproteinase inhibitors for wound healing |
US20050120392A1 (en) | 2002-02-28 | 2005-06-02 | Rubinstein Amy L. | Transgenic zebrafish models for thrombosis |
US7438925B2 (en) | 2002-08-26 | 2008-10-21 | Biovention Holdings Ltd. | Drug eluting coatings for medical implants |
WO2004073504A2 (en) * | 2003-02-20 | 2004-09-02 | Proteon Therapeutics, Llc | Methods for the treatment and prevention of diseases of biological conduits |
US20050025705A1 (en) | 2003-07-22 | 2005-02-03 | Xinkang Wang | Thrombosis animal models and their use in drug discovery and development |
CA2560507C (en) | 2004-03-26 | 2011-08-16 | Surmodics, Inc. | Composition and method for preparing biocompatible surfaces |
US20080069814A1 (en) * | 2005-01-05 | 2008-03-20 | Novacea, Inc. | Prevention of Thrombotic Disorders with Active Vitamin D Compounds or Mimics Thereof |
JP5178506B2 (ja) | 2005-03-14 | 2013-04-10 | バイオベンション ホールディングス リミテッド | ドラッグデリバリー組成物と関連する方法 |
WO2006126182A2 (en) * | 2005-05-24 | 2006-11-30 | Inspire M.D Ltd. | Stent apparatuses for treatment via body lumens and methods of use |
US20080214599A1 (en) | 2005-08-19 | 2008-09-04 | John Thomas Brandt | Use of Par-1/Par-4 Inhibitors for Treating or Preventing Vascular Diseases |
WO2007062376A2 (en) | 2005-11-21 | 2007-05-31 | Florida Atlantic University | Selective inhibition of matrix metalloproteinases |
US7888483B2 (en) | 2006-07-18 | 2011-02-15 | Irm Llc | Antagonists of protease activated receptor-1 (PAR1) |
JP4861115B2 (ja) * | 2006-09-28 | 2012-01-25 | サントリーホールディングス株式会社 | ラベル、ラベルの製造方法、ラベルの線剥離強度の経時安定化方法、及び容器 |
US7838232B2 (en) * | 2006-10-19 | 2010-11-23 | Auburn University | CaIDAG-GEF1 gene mutations associated with thrombopathy in canines |
US9719191B2 (en) | 2006-11-29 | 2017-08-01 | The Research Foundation For The State University Of New York | Methods for identifying ligands that target nucleic acid molecules and nucleic acid structural motifs |
US7947447B2 (en) | 2007-01-16 | 2011-05-24 | Somalogic, Inc. | Method for generating aptamers with improved off-rates |
BRPI0809095A2 (pt) | 2007-03-23 | 2014-09-09 | Schering Corp | Redução de eventos adversos após intervenção percutânea através de uso de um antagonista de receptor de trombina |
WO2008116468A2 (en) * | 2007-03-26 | 2008-10-02 | Dako Denmark A/S | Mhc peptide complexes and uses thereof in infectious diseases |
US8383156B2 (en) | 2007-04-30 | 2013-02-26 | Cordis Corporation | Coating for a medical device having an anti-thrombotic conjugate |
US20090018646A1 (en) | 2007-07-10 | 2009-01-15 | Zhao Jonathon Z | Coating Employing an Anti-Thrombotic Conjugate |
WO2009119455A1 (ja) * | 2008-03-27 | 2009-10-01 | 国立大学法人東北大学 | がん細胞運動およびがん細胞浸潤抑制剤 |
WO2010119455A2 (en) * | 2009-04-15 | 2010-10-21 | Sun Pharma Advanced Research Company Ltd. | An injectable sustained release pharmaceutical composition |
-
2010
- 2010-04-12 CA CA2758322A patent/CA2758322C/en active Active
- 2010-04-12 EP EP15178959.1A patent/EP3061460A1/en not_active Withdrawn
- 2010-04-12 US US13/263,715 patent/US20120121706A1/en not_active Abandoned
- 2010-04-12 AU AU2010233089A patent/AU2010233089B2/en not_active Ceased
- 2010-04-12 EP EP15185115.1A patent/EP2990051B1/en not_active Not-in-force
- 2010-04-12 EP EP10762578.2A patent/EP2416799B1/en not_active Not-in-force
- 2010-04-12 DE DE202010018378.2U patent/DE202010018378U1/de not_active Expired - Lifetime
- 2010-04-12 JP JP2012504929A patent/JP2012523438A/ja active Pending
- 2010-04-12 WO PCT/US2010/030783 patent/WO2010118435A2/en active Application Filing
-
2014
- 2014-08-14 US US14/460,353 patent/US9376499B2/en active Active
-
2016
- 2016-05-26 US US15/165,988 patent/US20170065668A1/en not_active Abandoned
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2012523438A5 (ja) | ||
EP2605790B1 (en) | Intranasal delivery of cell permeant therapeutics | |
US20200384062A1 (en) | Use of inhibitors of il-36 proteolytic processing for the treatment and/or reduction of inflammation | |
WO2020060401A2 (en) | Bioactive peptides derived from snakes | |
KR20180037185A (ko) | 광범위의 항감염성 펩티드 | |
WO2013082045A1 (en) | Netrin loop peptide mimetics and uses thereof | |
JP5345069B2 (ja) | 低出血性抗凝固性融合タンパク質の調製および使用 | |
US9617325B2 (en) | Treatment of IgE-mediated disease | |
EP1468085B1 (en) | Synthetic peptides and uses thereof for the prevention and therapy of cancer invasion and metastasis | |
US20210275629A1 (en) | Compositions comprising sel1-derived peptides and methods of treatment/prevention of excess oxalate levels and associated conditions/diseases therewith | |
JP6971301B2 (ja) | ヒトにおける長時間作用性第ix因子の皮下投与 | |
US11439693B2 (en) | Vasoconstrictive and antibacterial combination treatment for rosacea | |
US20190085029A1 (en) | Cyclin-dependent kinase 5 (cdk5) inhibitory peptides | |
US8575103B2 (en) | Peptides and methods for inhibiting G alpha protein signaling | |
WO2006006954A3 (en) | Modified fusion peptides derived from a p53 domain against malignant and/or transformed mammalian cells | |
AU2003205658A1 (en) | Synthetic peptides and uses thereof for the prevention and therapy of cancer invasion and metastasis |